Akari Therapeutics expands ADC pipeline with new CEACAM5-targeting candidate AKTX-102.

Akari Therapeutics has filed a provisional patent application for AKTX-102, a new ADC candidate targeting CEACAM5, a well-validated but historically difficult-to-drug oncology target. CEACAM5 is expressed in various cancers, including colorectal, pancreatic, bladder, and lung adenocarcinomas. AKTX-102 leverages Akari's proprietary PH1 spliceosome payload and a novel antibody construct to address this challenging and valuable solid tumor target.